Evidence map›Paper›PMID 39660834›Full record

Trial reportThe New England journal of medicine2025

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O'Shaughnessy, Nadia Harbeck, Lisa A Carey and 20 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Giredestrant plus Everolimus in Advanced Breast Cancer.The New England journal of medicine · 2026
    Trial
  9. Trial
  10. Trial
  11. Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. AMCP Market Insights: Managed care approaches toJournal of managed care & specialty pharmacy · 2026
    Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Komal L JhaveriMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
Patrick NevenUniversity Hospitals Leuven, Leuven, Belgium.
Monica Lis CasalnuovoHospital María Curie, Buenos Aires.
Sung-Bae KimAsan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Eriko TokunagaNational Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Philippe AftimosInstitut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels.
Cristina SauraVall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona.
Joyce O'ShaughnessyBaylor University Medical Center, Texas Oncology, U.S. Oncology, Dallas.
Nadia HarbeckBreast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany.
Lisa A CareyUniversity of North Carolina at Chapel Hill, Chapel Hill.ORCID 0000-0003-2388-4649
Giuseppe CuriglianoUniversity of Milan, Milan.ORCID 0000-0003-1781-2518
Antonio Llombart-CussacHospital Arnau de Vilanova, Valencia, Spain.
Elgene LimGarvan Institute of Medical Research and University of New South Wales, Sydney.
María de la Luz García TinocoHospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City.
Joohyuk SohnYonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-2303-2764
André MattarMastology Department, Women's Health Hospital, São Paulo.
Qingyuan ZhangHarbin Medical University Cancer Hospital, Harbin, China.
Chiun-Sheng HuangNational Taiwan University Hospital and National Taiwan University College of Medicine, Taipei.
Chih-Chiang HungDivision of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan.
Jorge Luis Martinez RodriguezFilios Alta Medicina, Monterrey, Mexico.
Manuel Ruíz BorregoMedical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain.
Rikiya NakamuraDepartment of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan.
Kamnesh R PradhanEli Lilly, Indianapolis.
Christoph Cramer von LaueEli Lilly, Indianapolis.
Emily BarrettEli Lilly, Indianapolis.
Shanshan CaoEli Lilly, Indianapolis.
Xuejing Aimee WangEli Lilly, Indianapolis.
Lillian M SmythEli Lilly, Indianapolis.
François-Clément BidardInstitut Curie and University of Versailles Saint-Quentin-en-Yvelines-Paris-Saclay University, Paris.ORCID 0000-0001-5932-8949
EMBER-3 Study Group

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundImlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (

methodsIn a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib. Primary end points were investigator-assessed progression-free survival with imlunestrant as compared with standard therapy among patients with

resultsOverall, 874 patients underwent randomization, with 331 assigned to imlunestrant, 330 to standard therapy, and 213 to imlunestrant-abemaciclib. Among 256 patients with

conclusionsAmong patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesBenzopyransBreast NeoplasmsBreast Neoplasms, MaleAdultAgedAged, 80 and overAndrostadienesErb-b2 Receptor Tyrosine KinasesEstrogen Receptor alphaFemaleFulvestrantHumansMaleabemaciclibAminopyridinesAndrostadienesBenzimidazolesBenzopyransERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesESR1 protein, humanEstrogen Receptor alphaexemestaneFulvestrantImlunestrant

Identifiers

PMID39660834
PMCPMC13674379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.